Alector (ALEC) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Conference overview

• Presented at H.C. Wainwright's fifth annual Neuro Perspectives Virtual Conference, focusing on neurodegenerative disease innovation and late-stage clinical programs.

• Emphasized a 10-year track record, global pharma partnerships, and a strong financial position with $562 million in cash, providing runway through 2026.

• Highlighted a portfolio spanning late-stage and proprietary programs targeting severe unmet needs in neurodegeneration.

TREM2 program updates

• AL002, a TREM2-activating antibody for Alzheimer's, completed phase II enrollment; data expected Q4 2024.

• Over 90% of eligible patients entered the extension study, indicating strong engagement.

• Phase II design is robust, with multiple dose arms and comprehensive biomarker and imaging endpoints.

• ARIA observed in most patients, mostly as mild, transient imaging findings; serious cases are rare and manageable.

• AbbVie holds an option deal with a potential $250 million opt-in payment post-phase II, leading to a global 50/50 profit share or royalty arrangement.

Progranulin franchise and clinical progress

• Latozinemab, a progranulin-elevating antibody, is in phase III for FTD-GRN; enrollment completed ahead of target.

• Received FDA breakthrough, orphan drug, and fast track designations for latozinemab.

• Phase II open-label data showed restoration of progranulin and biomarkers to normal levels, with 50% slowing of disease progression over 12 months compared to controls.

• Phase III includes 103 symptomatic and 16 at-risk patients, with data expected late 2025 or early 2026.

• AL101, another progranulin antibody, is in phase II for early Alzheimer's, with a 76-week randomized study and rich biomarker analysis.